Condensed Consolidating Financial Information Level 3 (Tables)

6 Months Ended

Jun. 30, 2011

CONDENSED CONSOLIDATING FINANCIAL INFORMATION [Abstract]

Schedule of Condensed Financial Statements Balance Sheet [Table Text Block]

Condensed Consolidating Balance Sheets (Unaudited)
(In thousands)	June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	9,240	$	6,138	$	9,183	$	—		$	24,561
Accounts receivable, net	281		35,209		124,718		—			160,208
Inventories, net	—		4,264		38,244		—			42,508
Prepaid expenses and other current assets	6,122		8,632		12,660		—			27,414
Total current assets	15,643		54,243		184,805		—			254,691
PROPERTY, PLANT AND EQUIPMENT, net	—		20,921		84,205		—			105,126
GOODWILL AND INTANGIBLES, net	46,986		15,445		99,988		—			162,419
INTERCOMPANY RECEIVABLES	18,720		89,185		397,713		(505,618		)	—
INVESTMENT IN AFFILIATES	566,537		—		1,596,076		(2,161,801		)	812
DEFERRED TAX ASSET	2,453		—		5,978		(1,629		)	6,802
OTHER ASSETS	3,347		15,713		3,323		—			22,383
TOTAL ASSETS	$	653,686	$	195,507	$	2,372,088	$	(2,669,048	)	$	552,233
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	8,968	$	8,974	$	43,389	$	—		$	61,331
Short-term debt	—		89,747		—		—			89,747
Other accrued expenses	2,366		30,844		51,810		—			85,020
Total current liabilities	11,334		129,565		95,199		—			236,098
LONG-TERM DEBT	—		—		—		—			—
DEFERRED COMPENSATION	6,476		17,421		104		—			24,001
DEFERRED TAX LIABILITY	—		762		867		(1,629		)	—
INTERCOMPANY PAYABLES	372,606		—		133,012		(505,618		)	—
OTHER LONG-TERM LIABILITIES	14,207		2,963		20,579		—			37,749
Equity Component of Short-term Debt -Senior Exchangeable Notes	—		2,183		—		—			2,183
SHAREHOLDERS' EQUITY	249,063		42,613		2,119,188		(2,161,801		)	249,063
NON-CONTROLLING INTEREST	—		—		3,139		—			3,139
TOTAL EQUITY	249,063		42,613		2,122,327		(2,161,801		)	252,202
TOTAL LIABILITIES AND EQUITY	$	653,686	$	195,507	$	2,372,088	$	(2,669,048	)	$	552,233

Schedule of Condensed Financial Statements Prior Year Balance Sheet [Table Text Block]

Condensed Consolidating Balance Sheets
(In thousands)	December 31, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	11,162	$	88,612	$	34,106	$	—		$	133,880
Accounts receivable, net	10		33,637		121,079		—			154,726
Inventories, net	—		4,127		29,852		—			33,979
Prepaid expenses and other current assets	5,641		9,437		11,657		—			26,735
	16,813		135,813		196,694		—			349,320
PROPERTY, PLANT AND EQUIPMENT, net	—		21,139		83,084		—			104,223
GOODWILL AND INTANGIBLES, net	46,986		15,838		100,053		—			162,877
INTERCOMPANY RECEIVABLES	21,749		164,945		242,754		(429,448		)	—
INVESTMENT IN AFFILIATES	553,693		—		1,567,416		(2,120,414		)	695
DEFERRED TAX ASSET	2,810		—		6,436		(9,246		)	—
OTHER ASSETS	3,209		13,099		2,619		—			18,927
TOTAL ASSETS	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	336	$	5,144	$	39,230	$	—		$	44,710
Short-term debt	—		147,543		—		—			147,543
Other accrued expenses	2,291		29,250		55,559		—			87,100
	2,627		181,937		94,789		—			279,353
DEFERRED COMPENSATION	6,159		14,981		101		—			21,241
DEFERRED TAX LIABILITY	—		11,444		—		(9,246		)	2,198
INTERCOMPANY PAYABLES	333,651		—		95,797		(429,448		)	—
OTHER LONG-TERM LIABILITIES	13,332		1,099		17,615		—			32,046
Equity Component of Short-term Debt -Senior Exchangeable Notes	—		8,864		—		—			8,864
SHAREHOLDERS' EQUITY	289,491		132,509		1,987,905		(2,120,414		)	289,491
NON-CONTROLLING INTEREST	—		—		2,849		—			2,849
TOTAL EQUITY	289,491		132,509		1,990,754		(2,120,414		)	292,340
TOTAL LIABILITIES AND EQUITY	$	645,260	$	350,834	$	2,199,056	$	(2,559,108	)	$	636,042

Schedule of Condensed Financial Statements Income Statement Quarter [Table Text Block]

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	52,935		$	172,850		$	—		$	225,785
Intercompany revenue	409		6,314			30,838			(37,561		)	—
Earnings (loss) from consolidated affiliates	48,014		—			90,507			(138,521		)	—
Total revenue	48,423		59,249			294,195			(176,082		)	225,785
OPERATING EXPENSES
Operating costs	264		26,698			125,311			—			152,273
General and administrative expenses	1,971		7,784			2			—			9,757
Depreciation and amortization	—		1,599			4,206			—			5,805
Other (income) expense, net	814		3,664			29,915			(34,246		)	147
Operating income	45,374		19,504			134,761			(141,836		)	57,803
Loss on exchange of Senior Exchangeable Notes	—		210			—			—			210
Interest expense	—		24,256			—			(21,757		)	2,499
Income (loss) before income tax expense	45,374		(4,962		)	134,761			(120,079		)	55,094
Income tax expense (benefit)	4,923		(8,436		)	18,223			—			14,710
Net income	40,451		3,474			116,538			(120,079		)	40,384
Net income (loss) attributable to non-controlling interest	—		—			(67		)	—			(67		)
Net income (loss) attributable to Core Laboratories	$	40,451	$	3,474		$	116,605		$	(120,079	)	$	40,451

Schedule of Condensed Financial Statements Income Statement YTD [Table Text Block]

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—		$	100,735		$	331,783		$	—		$	432,518
Intercompany revenue	769			11,695			70,894			(83,358		)	—
Earnings (loss) from consolidated affiliates	86,708			—			70,803			(157,511		)	—
Total revenue	87,477			112,430			473,480			(240,869		)	432,518
OPERATING EXPENSES
Operating costs	558			51,997			236,468			—			289,023
General and administrative expenses	4,615			14,654			12			—			19,281
Depreciation and amortization	—			3,229			8,407			—			11,636
Other (income) expense, net	943			6,609			56,342			(65,618		)	(1,724		)
Operating income	81,361			35,941			172,251			(175,251		)	114,302
Loss on exchange of Senior Exchangeable Notes	—			839			—			—			839
Interest expense	—			83,009			—			(78,150		)	4,859
Income (loss) before income tax expense	81,361			(47,907		)	172,251			(97,101		)	108,604
Income tax expense (benefit)	(5,380		)	10,991			16,617			—			22,228
Net income	86,741			(58,898		)	155,634			(97,101		)	86,376
Net income (loss) attributable to non-controlling interest	—			—			(365		)	—			(365		)
Net income (loss) attributable to Core Laboratories	$	86,741		$	(58,898	)	$	155,999		$	(97,101	)	$	86,741

Schedule of Condensed Financial Statements Cash Flow [Table Text Block]

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2011
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by (used in) operating activities	$	128,131		$	(14,422	)	$	(15,755	)	$	—	$	97,954
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(1,256		)	(10,728		)	—		(11,984		)
Patents and other intangibles	—			(16		)	(116		)	—		(132		)
Proceeds from sale of assets	—			34			137			—		171
Proceeds from insurance recovery	—			—			884			—		884
Premiums on life insurance	—			(1,243		)	—			—		(1,243		)
Net cash used in investing activities	—			(2,481		)	(9,823		)	—		(12,304		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt borrowings	—			(64,477		)	—			—		(64,477		)
Stock options exercised	241			—			—			—		241
Excess tax benefits from stock-based compensation	2,289			—			—			—		2,289
Debt financing costs	—			(1,094		)	—			—		(1,094		)
Settlement of Warrants	(57,777		)	—			—			—		(57,777		)
Non-controlling interest - contributions	—			—			895			—		895
Non-controlling interest - dividends	—			—			(240		)	—		(240		)
Dividends paid	(22,709		)	—			—			—		(22,709		)
Repurchase of common shares	(52,097		)	—			—			—		(52,097		)
Net cash provided by (used in) financing activities	(130,053		)	(65,571		)	655			—		(194,969		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(1,922		)	(82,474		)	(24,923		)	—		(109,319		)
CASH AND CASH EQUIVALENTS, beginning of period	11,162			88,612			34,106			—		133,880
CASH AND CASH EQUIVALENTS, end of period	$	9,240		$	6,138		$	9,183		$	—	$	24,561

Schedule of Condensed Financial Statements Income Statement Prior Year Quarter [Table Text Block]

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Three Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	48,386	$	150,516	$	—		$	198,902
Intercompany revenue	379		7,619		35,451		(43,449		)	—
Earnings from consolidated affiliates	37,709		—		115,745		(153,454		)	—
Total revenue	38,088		56,005		301,712		(196,903		)	198,902
OPERATING EXPENSES
Operating costs	322		25,237		103,358		—			128,917
General and administrative expenses	2,147		7,060		4		—			9,211
Depreciation and amortization	—		1,554		4,212		—			5,766
Other (income) expense, net	992		3,411		29,884		(32,999		)	1,288
Operating income	34,627		18,743		164,254		(163,904		)	53,720
Loss on exchange of Senior Exchangeable Notes	—		—		—		—			—
Interest expense	—		4,112		2		—			4,114
Income before income tax expense	34,627		14,631		164,252		(163,904		)	49,606
Income tax expense (benefit)	411		5,992		8,841		—			15,244
Net income	34,216		8,639		155,411		(163,904		)	34,362
Net income attributable to non-controlling interest	—		—		146		—			146
Net income attributable to Core Laboratories	$	34,216	$	8,639	$	155,265	$	(163,904	)	$	34,216

Schedule of Condensed Financial Statements Income Statement Prior Year YTD [Table Text Block]

Condensed Consolidating Statements of Operations (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)		Core Laboratories LP (Issuer)		Other Subsidiaries (Non- Guarantors)		Consolidating Adjustments			Consolidated Total
REVENUE
Operating revenue	$	—	$	93,547	$	293,692	$	—		$	387,239
Intercompany revenue	667		12,206		70,960		(83,833		)	—
Earnings from consolidated affiliates	72,898		—		216,504		(289,402		)	—
Total revenue	73,565		105,753		581,156		(373,235		)	387,239
OPERATING EXPENSES
Operating costs	712		50,221		203,572		—			254,505
General and administrative expenses	4,314		11,270		7		—			15,591
Depreciation and amortization	—		3,112		8,408		—			11,520
Other (income) expense, net	857		5,002		58,192		(63,561		)	490
Operating income	67,682		36,148		310,977		(309,674		)	105,133
Interest expense	—		8,167		6		—			8,173
Income before income tax expense	67,682		27,981		310,971		(309,674		)	96,960
Income tax expense (benefit)	1,261		11,474		17,577		—			30,312
Net income	66,421		16,507		293,394		(309,674		)	66,648
Net income attributable to non-controlling interest	—		—		227		—			227
Net income attributable to Core Laboratories	$	66,421	$	16,507	$	293,167	$	(309,674	)	$	66,421

Schedule of Condensed Financial Statements Cash Flow Prior Year [Table Text Block]

Condensed Consolidating Statements of Cash Flows (Unaudited)
(In thousands)	Six Months Ended June 30, 2010
	Core Laboratories N.V. (Parent/ Guarantor)			Core Laboratories LP (Issuer)			Other Subsidiaries (Non- Guarantors)			Consolidating Adjustments		Consolidated Total
Net cash provided by operating activities	$	54,349		$	44,964		$	12,047		$	—	$	111,360
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—			(2,918		)	(9,778		)	—		(12,696		)
Patents and other intangibles	—			—			(142		)	—		(142		)
Acquisitions, net of cash	—			(9,000		)	—			—		(9,000		)
Proceeds from sale of assets	—			11			114			—		125
Premiums on life insurance	—			(921		)	—			—		(921		)
Net cash used in investing activities	—			(12,828		)	(9,806		)	—		(22,634		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock options exercised	295			—			—			—		295
Excess tax benefit from stock-based payments	798			—			—			—		798
Non-controlling interest - dividends	—			—			(181		)	—		(181		)
Dividends paid	(5,375		)	—			—			—		(5,375		)
Repurchase of common shares	(91,686		)	—			—			—		(91,686		)
Net cash used in financing activities	(95,968		)	—			(181		)	—		(96,149		)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(41,619		)	32,136			2,060			—		(7,423		)
CASH AND CASH EQUIVALENTS, beginning of period	73,998			95,048			11,999			—		181,045
CASH AND CASH EQUIVALENTS, end of period	$	32,379		$	127,184		$	14,059		$	—	$	173,622